Arvinas' ARV-102 Shows >50% LRRK2 Degradation in Positive Parkinson's Phase 1 Data
ARVN has more than doubled off its 52-week low of $5.9.
Summary
Arvinas announced positive Phase 1 clinical trial data for its investigational drug ARV-102, demonstrating greater than 50% degradation of LRRK2 in the cerebrospinal fluid (CSF) of Parkinson's disease patients after 28 days of treatment. The drug was also well tolerated across all dose levels. This is a significant development for the clinical-stage biotech, as the data indicates strong target engagement and brain penetration, crucial for a neurodegenerative disease therapy. The reduction in LRRK2 and related biomarkers suggests potential therapeutic efficacy, substantially de-risking the program. The company plans to initiate a Phase 1b clinical trial in progressive supranuclear palsy (PSP) in Q2 2026, with the potential for a registrational trial in late 2026, while continuing to evaluate development options for Parkinson's disease. These upcoming milestones will be critical catalysts.
At the time of this announcement, ARVN was trading at $12.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $768.2M. The 52-week trading range was $5.90 to $14.51. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.